Fujitsu Ltd.

12/05/2024 | Press release | Archived content

Nichi-Iko and Fujitsu drive pharmaceutical manufacturing DX with AI

Nichi-Iko and Fujitsu drive pharmaceutical manufacturing DX with AI

Joint field trial aims to eliminate product waste, accelerate training of manufacturing engineers

Nichi-Iko Pharmaceutical Co., Ltd., Fujitsu Limited

Toyama and Kawasaki, Japan, December 5, 2024

Nichi-Iko Pharmaceutical Co., Ltd. and Fujitsu Limited today announced the ongoing progress of a joint field trial. The initiative aims to aid the detection of omissions in sterile room entry and exit procedures and enhance the training of manufacturing engineers at Nichi-Iko's pharmaceutical manufacturing facility. It leverages Fujitsu's behavioral analysis AI service, "Fujitsu Kozuchi for Vision", and Broadleaf Co., Ltd.'s productivity and business optimization software, "OTRS" and "OTRS+AI."

Joint field trial outline

1. Trial period:
November 19, 2024 - December 20, 2024

2. Location:
Nichi-Iko Pharmaceutical Co., Ltd. Gifu Plant (Takayama City, Gifu Prefecture, Japan)

3. Details:

  • Fujitsu's Fujitsu Kozuchi for Vision AI service, equipped with technology that detects human actions in real-time (1), will be used to analyze video data from cameras at the sterile room entrance. The system will verify whether standardized procedures are followed during entry and exit and detect omissions in real-time. The partners are considering various notification methods, including alarms, flashing lights, and smartphone alerts. By ensuring adherence to correct procedures, the goal is to eliminate product waste from non-standard operations and ensure stability in aseptic drug manufacturing.
Figure: Detection of normal behavior (left) and problematic squatting (right)
Figure: Detection of the action of dust removal work
Figure: Detection of hand washing by multiple people at the same time
  • To address the ongoing employee shortage in the pharmaceutical sector and accelerate the training of manufacturing engineers, Broadleaf solutions OTRS and OTRS+AI, the latter of which incorporates Fujitsu's work segmentation AI technology (2), will be implemented. Video data of experienced engineers carrying out their work will be segmented by individual task and used to train the AI. Next, the AI automatically segments the video data of the novice engineers carrying out their tasks and displays both segmented videos side-by-side for an instructor to use in training. Additionally, a video-based standard operating procedure manual and pre-operation simulations will be created with a view to achieving a 50% reduction in training costs compared to conventional methods.
Figure: Motion comparison with parallel display of experienced engineers (left) and novice engineers (right)

Future Plans

Based on the results of this joint field trial, both companies will work towards the full-scale introduction of Fujitsu Kozuchi for Vision, OTRS, and OTRS+AI at the Nichi-Iko Gifu plant by March 2025.

Nichi-Iko will leverage the knowledge gained from this joint field trial to establish the Nichi-Iko Gifu plant as a model smart factory. By replicating this model across all its plants in Japan, Nichi-Iko aims to accelerate DX across its manufacturing and contribute to the stable supply of pharmaceuticals.

Fujitsu will continue to support Nichi-Iko's smart factory initiatives and DX efforts in pharmaceutical manufacturing.

  • [1]
    Technology that detects human actions in real-time :
    Enables real-time detection by accurately identifying and sequencing individual steps within a task, even those difficult to detect (patent pending).
  • [2]
    Work segmentation AI technology :
    Enables high-precision automatic detection of individual tasks from video content by trained AI.

Related Links



About Fujitsu

Fujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.

Press Contacts

Nichi-Iko Pharmaceutical Co., Ltd.
Tel : (+81)076-442-7026

Fujitsu Limited
Public and Investor Relations Division
Inquiries

All company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.


Date: 5 December, 2024
City: Toyama and Kawasaki, Japan
Company: Nichi-Iko Pharmaceutical Co., Ltd., Fujitsu Limited